Результаты поиска - Stefan Willmann

  • Отображение 1 - 14 результаты of 14
Отмена результатов
  1. 1
    Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®

    Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim® по Stefan Willmann, Kirstin Thelen, Jörg Lippert

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  2. 2
    First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development

    First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development по Ashley Strougo, Thomas Eißing, Ashraf Yassen, Stefan Willmann, Meindert Danhof, Jan Freijer

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study

    Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study по Heino Staß, Johannes Nagelschmitz, Stefan Willmann, Heinz Delesen, Abhishek Gupta, Sybille Baumann

    Опубликовано 2013
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  4. 4
    Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models

    Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models по M. Vossen, Michael Sevestre, Christoph Niederalt, In‐Jin Jang, Stefan Willmann, Andrea N. Edginton

    Опубликовано 2007
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data

    Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data по Karina Claassen, Kirstin Thelen, Katrin Coboeken, Thomas Gaub, Jörg Lippert, Karel Allegaert, Stefan Willmann

    Опубликовано 2015
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  6. 6
    A Generic Integrated Physiologically based Whole‐body Model of the Glucose‐Insulin‐Glucagon Regulatory System

    A Generic Integrated Physiologically based Whole‐body Model of the Glucose‐Insulin‐Glucagon Regulatory System по Stephan Schaller, Stefan Willmann, Jörg Lippert, L. Schaupp, Thomas R. Pieber, Andreas Schuppert, Thomas Eißing

    Опубликовано 2013
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals

    Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals по Jan‐Frederik Schlender, Michaela Meyer, Kirstin Thelen, Markus Krauß, Stefan Willmann, Thomas Eißing, Ulrich Jaehde

    Опубликовано 2016
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim

    A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim по Christoph Niederalt, Lars Kuepfer, Juri Solodenko, Thomas Eißing, Hans‐Ulrich Siegmund, Michael S. Block, Stefan Willmann, Jörg Lippert

    Опубликовано 2017
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations

    Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations по Stefan Willmann, Liping Zhang, Matthias Frede, Dagmar Kubitza, Wolfgang Mueck, Stephan Schmidt, Alexander Solms, Xiaoyu Yan, Dirk Garmann

    Опубликовано 2018
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model

    Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model по Lars Kuepfer, Christoph Niederalt, Thomas Wendl, J‐F Schlender, Stefan Willmann, Jörg Lippert, Michael S. Block, Thomas Eißing, Donato Teutonico

    Опубликовано 2016
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban

    Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban по Stefan Willmann, Corina Becker, Rolf Burghaus, Katrin Coboeken, Andrea N. Edginton, Jörg Lippert, Hans‐Ulrich Siegmund, Kirstin Thelen, Wolfgang Mück

    Опубликовано 2013
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

    Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study по Stefan Willmann, Kirstin Thelen, Dagmar Kubitza, Anthonie W.A. Lensing, Matthias Frede, Katrin Coboeken, Jan Stampfuss, Rolf Burghaus, Wolfgang Mück, Jörg Lippert

    Опубликовано 2018
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients

    PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients по Stefan Willmann, Eleonora Marostica, Nelleke Snelder, Alexander Solms, Markus Jensen, Maximilian T. Lobmeyer, Anthonie W.A. Lensing, Claudette Bethune, Erin Morgan, Rosie Z. Yu, Yanfeng Wang, Shiangtung W. Jung, Richard S. Geary, Sanjay Bhanot

    Опубликовано 2021
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  14. 14
    Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation

    Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation по Guy Young, Anthonie W.A. Lensing, Paul Monagle, Christoph Male, Kirstin Thelen, Stefan Willmann, Joseph S. Palumbo, Riten Kumar, Ildar Nurmeev, Kerry Hege, Fanny Bajolle, Philip Connor, Hélène L. Hooimeijer, Marcela Torres, Anthony K.C. Chan, Gili Kenet, Susanne Holzhauer, Amparo Santamaría, Pascal Amédro, Jan Beyer‐Westendorf, Ida Martinelli, M. Patricia Massicotte, William T. Smith, Scott D. Berkowitz, Stephan Schmidt, Victoria Price, Martin H. Prins, Dagmar Kubitza

    Опубликовано 2020
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: